Japan Panel OKs Expensive Gene Therapy for Spinal Muscular Atrophy
The health minister is expected to formally approve the therapy, Zolgensma, by the end of March, with public health insurance coverage seen starting this summer. The therapy, which has already been approved in the United States, is expensive, costing the dollar equivalent of 230 million yen in the country for one-time infusion.





